As a neurologist with more than 30 years in the field of Alzheimer’s disease, I have had many heartbreaking conversations with patients and their loved ones. More than 6 million people in America are living with Alzheimer’s disease, and that staggering number is expected to double within the next 30 years unless there is a change. However, I am more optimistic about that change and physicians’ ability to slow the course of this devastating illness than I have ever been in the past.

Approved in 2016, the newly updated label changes add more clarity to the use of pimavanserin, noting that patients with Parkinson disease with dementia may be eligible for treatment.

The US Food & Drug Administration (FDA) has made 2 updates to the packaging label for an approved treatment for Parkinson disease psychosis.

Clinicians from Switzerland are urging caution when prescribing an anti-amyloid medication in a patient with Alzheimer's disease (AD) also taking a selective serotonin reuptake inhibitor (SSRI) antidepressant.

A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies.

With three positive and three negative Phase 3 trials of second-generation anti-amyloid antibodies to draw upon, Alzheimerologists now have more data to mine for what works and what does not. At last month’s Alzheimer’s Association International Conference in Amsterdam, scientists pored over gantenerumab and lecanemab data, hunting for clues of which parameters might predict success. And clues they found.

93% of patients in study had an antibody response against beta-amyloid

Patients starting SSRIs and lecanemab may warrant close monitoring

The immunotherapy drug, UB-311, developed by vaxxinity, has shown promising results in a Phase 2a clinical trial for the treatment of mild Alzheimer’s disease. The trial data, published in The Lancet’s eBioMedicine journal, indicates that UB-311 is safe and well tolerated and demonstrates a tendency to slow cognitive decline in patients with mild Alzheimer’s.

UB-311 could offer multiple competitive advantages over licensed passive immunotherapies, including less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of ARIA-E

The drugs clear sticky plaques from the brain. But they are not for everyone, experts caution

he latest report on clinical trials in the Alzheimer’s drug development pipeline points to the growing potential of anti-amyloid monoclonal antibodies for treating the brain-robbing condition. Anti-inflammatory agents comprise the single largest therapeutic category with 25 drugs, but astoundingly no two are aimed at the same target, according to lead author Jeffrey Cummings, M.D., research professor in the school of integrated health sciences at the University of Nevada, Las Vegas, and director of its Chambers-Grundy Center for Transformative Neuroscience.